The global anesthesia CO2 absorbent market size reached USD 82.9 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 132.8 Million by 2033, exhibiting a growth rate (CAGR) of 5.38% during 2025-2033. The increasing number of surgeries across hospitals and clinics is raising the demand for reliable absorbents, which is stimulating the market.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 82.9 Million |
Market Forecast in 2033
|
USD 132.8 Million |
Market Growth Rate 2025-2033 | 5.38% |
Growing Demand for Eco-Friendly Solutions
Healthcare providers are increasingly seeking CO2 absorbents that minimize harmful side effects, as environmental concerns are growing. In addition, eco-friendly absorbents reduce the ecological footprint of anesthesia practices and align with sustainability initiatives within hospitals, thereby promoting safer alternatives that contribute to a healthier environment while maintaining effective patient care. For instance, in May 2024, according to an article published by Bell Medical Inc., the sodium hydroxide-free amsorb plus CO2 absorbent is promoting eco-friendly anesthesia by preventing harmful byproducts, and enabling low fresh gas flow techniques, thereby reducing anesthetic agent pollution, improving sustainability, and elevating anesthesia CO2 absorbent market scope.
Advancements in Low-Flow Anesthesia Technologies
The rising shift towards low-flow anesthesia techniques enhances patient outcomes and reduces wasteful gas usage. Moreover, innovations in CO2 absorbents that support these technologies facilitate doctors to maintain effective ventilation with lower fresh gas flows, thereby optimizing resource utilization and ensuring efficient gas management in surgical environments. For instance, in August 2024, Penlon launched the E-Flo 6C anesthesia machine, featuring absorber and CO2 monitoring, thereby enhancing safety and precision in low-flow anesthesia through advanced ventilation control and comprehensive gas monitoring systems. As per the anesthesia CO2 absorbent market segmentation, this is acting as a significant growth-inducing factor.
Improved Integration of CO2 Absorption Systems
Enhanced integration of CO2 absorption within anesthesia machines simplifies the operational setup, reducing the need for multiple connections between components. In contrast, this leads to faster assembly and improved usability, making it simpler to manage anesthesia procedures efficiently while ensuring optimal CO2 absorption performance, particularly in critical anesthesia environments. For instance, in October 2024, Philips introduced the Siesta i Whispa anesthesia machine, an integrated breathing system (IBS) with an ascending bag-in-bottle and CO2 absorber. This innovation streamlines connections between the machine and patient, reducing setup time and improving cleaning efficiency.
IMARC Group provides an analysis of the key trends in each segment of the market, along with the anesthesia CO2 absorbent market forecast at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on product, type, and end user.
Breakup by Product:
Medisorb currently hold the largest anesthesia CO2 absorbent market share
The report has provided a detailed breakup and analysis of the market based on the product. This includes soda lime, medisorb, dragersorb, amsorb, litholyme, and others. According to the report, medisorb represented the largest market segmentation.
Medisorb exhibits a clear dominance in the market due to its efficient CO2 absorption capabilities, which enhance patient safety during procedures. For example, Medisorb EF was launched to minimize compound formation, thereby ensuring better anesthesia care while reducing environmental impact in medical settings.
Breakup by Type:
Premium currently holds the largest anesthesia CO2 absorbent market demand
The report has provided a detailed breakup and analysis of the market based on the type. This includes premium and traditional. According to the report, premium represented the largest market segmentation.
The premium segment dominates the market due to its high efficiency, longer-lasting performance, and superior safety features. For example, Drager launched its premium product ‘Dragersorb’ with enhanced CO2 absorption capabilities, which reduces the risk of compound A formation, ensuring patient safety during anesthesia procedures.
Breakup by End User:
Hospital exhibits the largest anesthesia CO2 absorbent market outlook
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospital, clinics, and others. According to the report, the hospital represented the largest market segmentation.
Hospitals lead the market as the primary end users, driven by the need for efficient patient care during surgeries. For example, GE Healthcare launched Aisys CS2, an advanced anesthesia machine incorporating CO2 absorbents to enhance safety and reduce environmental impact.
Breakup by Region:
North America currently dominates the market
The anesthesia CO2 absorbent market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
As per the anesthesia CO2 absorbent market overview, North America dominates the market, which is driven by well-established healthcare systems, high surgical volumes, and innovative advancements. In addition, the region's dominance is also supported by growing awareness of patient safety and effective waste gas management during surgeries. For example, Drager launched its ‘Dragersorb Free’ absorbent, a CO2 absorbent designed to prevent the formation of toxic compounds during anesthesia. Furthermore, such innovations highlight North America's role in advancing safe and efficient anesthesia practices.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all market companies have also been provided. Some of the key players in the market include:
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Scope of the Report | Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Products Covered | Soda Lime, Medisorb, Dragersorb, Amsorb, Litholyme, Others |
Types Covered | Premium, Traditional |
End Users Covered | Hospitals, Clinics, Others |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Armstrong Medical Ltd. (Eakin Healthcare Group Ltd), Atrasorb, Drägerwerk AG & Co. KGaA, General Electric Company, Intersurgical Ltd., Löwenstein Medical SE & Co. KG, Micropore Inc., Molecular Products Group plc (Filtration Group Corporation), Smiths Medical Inc. (ICU Medical Inc.), etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global anesthesia CO2 absorbent market was valued at USD 82.9 Million in 2024.
We expect the global anesthesia CO2 absorbent market to exhibit a CAGR of 5.38% during 2025-2033.
The rising incidences of chronic conditions, such as cardiac disorders, neurological conditions, respiratory diseases, etc., along with the growing demand for anesthesia CO2 absorbent, as they absorb exhaled gases during anesthesia administration, are primarily driving the global anesthesia CO2 absorbent market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective surgical procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for anesthesia CO2 absorbent.
Based on the product, the global anesthesia CO2 absorbent market can be segmented into soda lime, medisorb, dragersorb, amsorb, litholyme, and others. Currently, medisorb holds the majority of the total market share.
Based on the type, the global anesthesia CO2 absorbent market has been divided into premium and traditional, where premium currently exhibits a clear dominance in the market.
Based on the end user, the global anesthesia CO2 absorbent market can be categorized into hospitals, clinics, and others. Currently, hospitals account for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global anesthesia CO2 absorbent market include Armstrong Medical Ltd. (Eakin Healthcare Group Ltd), Atrasorb, Drägerwerk AG & Co. KGaA, General Electric Company, Intersurgical Ltd., Löwenstein Medical SE & Co. KG, Micropore Inc., Molecular Products Group plc (Filtration Group Corporation), and Smiths Medical Inc. (ICU Medical Inc.).